| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8445202 | European Journal of Cancer | 2013 | 7 Pages |
Abstract
Among patients with ABTC, 25% received CT2, typically younger patients and those with longer PFS following CT1. Disease control occurred in 43% of patients, and more often with a doublet than a single agent. However, clearly more effective therapies must be found.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Thomas Walter, Anne M. Horgan, Mairead McNamara, Liz McKeever, Trisha Min, David Hedley, Stefano Serra, Monika K. Krzyzanowska, Eric Chen, Helen Mackay, Ronald Feld, Malcolm Moore, Jennifer J. Knox,